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with cirrhosis of other aetiologies (COE). The authors
point to the absence of patients with alcoholic liver dis-
ease (ALD) among patients with COE in our study [2].
Indeed, our study diﬀered in its primary goal and se-
lected population from their recent publication [3] that
demonstrated a high prevalence of coronary artery dis-
ease among patients with predominantly alcoholic cir-
rhosis. The primary objective of our study was to
evaluate the relationship between NASH-related cirrho-
sis and coronary artery disease (CAD), compared with
other aetiologies of cirrhosis, in a population that had
undergone liver transplantation. The selection bias in
our age and sex-matched COE group, comprised of only
patients with viral hepatitis and cholestatic liver disease,
reﬂects the leading causes of liver cirrhosis in patients
undergoing liver transplantation at our center. ‘‘Pure”
alcoholic cirrhosis is an unusual indication for liver
transplantation at our center, although in a signiﬁcant
number of patients with hepatitis C, alcohol is consid-
ered a contributing factor to the development of
cirrhosis.
The data discussed in the letter by Kalaitzakis and
Bjo¨rnsson conﬁrms a high prevalence of CAD in patients
with NASH-related cirrhosis compared to cirrhosis sec-
ondary to other causes (excluding ALD) which supports
our observations [2]. However, their ﬁnding of a high
prevalence of CAD in ALD-cirrhosis is interesting and
unexpected, given the results of previous autopsy studies
[4,5] and the protective eﬀect of moderate alcohol con-
sumption on atherosclerosis suggested by many other
studies [6,7]. In their study population [1,3] the incidence
of important risk factors for CAD including age, smok-
ing, male gender, hypertension and diabetes were higher
in ALD-cirrhosis compared to their COE group. These
ﬁndings not only point to the consistent importance of
cardiovascular risk factors in determining the risk of
CAD in a group (ALD) conventionally considered to
be protected from CAD, but also raise the important
question of the relative contribution of alcohol and met-
abolic factors in the pathogenesis of cirrhosis in their pa-
tients etiologically classiﬁed as ALD.
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The multi-centre study, by Bochud et al. [1], demon-
strating an association between hepatitis C virus (HCV)
genotype 3 and rapid progression of liver ﬁbrosis in
chronically infected patients, ampliﬁes the potential clin-
ical meaning of HCV genotypes, originally identiﬁed as
predictors of interferon therapy outcome. The report
from Switzerland corroborates the increasing evidence
that the natural history of hepatitis C may be also inﬂu-
enced by the genotype of HCV in addition to host andenvironmental co-factors of morbidities. The road to
HCV genotype being a modiﬁer of the course of HCV
infection was opened a long time ago by HCV-1, shown
to be associated with rapid progression of recurrent hep-
atitis C in liver transplanted patients [2], and with in-
creased risk of hepatocellular carcinoma (HCC) in
patients with cirrhosis [3], and by HCV-2 associated
with ALT ﬂares that ultimately accelerate the course
of chronic hepatitis in untreated patients [4]. In this con-
text, the paper by Bochud et al. adds nicely to these ﬁnd-
ings, as it shows HCV-3 to be associated with an accel-
erated deposition of ﬁbrosis in the liver.
To externally validate these ﬁndings we assessed a
cohort of patients prospectively followed at our centre
between December 2008 and May 2009. Of the 3566
patients with chronic HCV infection consecutively
admitted to our centre for biochemical and clinical eval-
uation, 327 (9%) knew the date of infection and had
undergone at least one liver biopsy before any antiviral
treatment. All liver biopsy specimens were considered
adequate for ﬁbrosis assessment [5]. Fibrosis was quan-
tiﬁed by the Ishak staging system, with scores ranging
from 0, representing no ﬁbrosis to 6 representing
cirrhosis [6].
At variance with the study population described by
Bochud et al. where the majority of patients acquired
HCV through intra-venous drug abuse (IVDA), two-
thirds of our patients with the known data of infection
identiﬁed blood transfusions as the relevant risk factor
for HCV infection (Table 1). Compared to Bochud’s
study, our patients were slightly older (median age at
biopsy 47 vs. 42 years) while they had a comparable
duration of HCV infection in years (23 vs. 21 years).
Consistent with Bochud’s observation, we noticed a fas-
ter progression of liver ﬁbrosis in HCV-3 patients.
Among the 327 patients of our cohort 134 (41%) devel-
oped a signiﬁcant degree of ﬁbrosis, deﬁned as an Ishak
staging score P3. While the proportion of patients
developing a signiﬁcant ﬁbrosis was not inﬂuenced by
HCV genotype (HCV-1: 68/143, 48%; HCV-2: 28/104,
27%; HCV-3: 38/80, 47%), when comparing the mean
disease duration in these patients signiﬁcant diﬀerences
emerged. In fact, the mean time lag necessary to develop
a signiﬁcant ﬁbrosis was 28.3 years for HCV-1, 24.2
years for HCV-2 patients and 21.8 years for HCV-3 in-
fected patients (p = 0.03). We omitted to calculate the
pace of ﬁbrosis progression in units per year since we
think that it is intrinsically ﬂawed, as the authors cor-
rectly point out, since not only it assumes that ﬁbrosis
progression is constant over time, a ﬁnding that has
been proven incorrect [7], but also it transforms a qual-
itative variable, such as the pattern of ﬁbrosis deposition
in the liver, into a quantitative variable [8].
The demonstration that HCV-3 genotype is a rele-
vant modiﬁer of the natural history of chronic infection
further supports anticipated treatment of these patients,
whenever possible.
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